Merck KGaA (OTCMKTS:MKKGY – Get Free Report) is expected to post its resultson Wednesday, May 13th. Analysts expect Merck KGaA to post earnings of $0.45 per share and revenue of $5.9425 billion for the quarter.
Merck KGaA (OTCMKTS:MKKGY – Get Free Report) last issued its quarterly earnings data on Thursday, March 5th. The company reported $0.28 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.47 by ($0.19). The company had revenue of $6.11 billion for the quarter, compared to analysts’ expectations of $6.20 billion. Merck KGaA had a return on equity of 9.03% and a net margin of 12.31%. On average, analysts expect Merck KGaA to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.
Merck KGaA Stock Performance
Shares of MKKGY opened at $26.01 on Wednesday. The stock’s 50-day simple moving average is $26.31 and its 200 day simple moving average is $27.52. Merck KGaA has a 52-week low of $23.73 and a 52-week high of $31.00. The stock has a market capitalization of $16.81 billion, a price-to-earnings ratio of 11.56, a price-to-earnings-growth ratio of 2.32 and a beta of 0.97. The company has a debt-to-equity ratio of 0.37, a quick ratio of 0.96 and a current ratio of 1.46.
Wall Street Analysts Forecast Growth
Check Out Our Latest Analysis on MKKGY
Merck KGaA Company Profile
Merck KGaA, Darmstadt, Germany, commonly referred to as Merck Group, is a multinational science and technology company with origins dating back to 1668. The company develops and manufactures products and technologies across healthcare, life science and electronics applications. It is distinct from the U.S. pharmaceutical company Merck & Co; Merck KGaA is a European group headquartered in Darmstadt and is publicly listed in Germany with an OTC American depositary receipt available under the symbol MKKGY.
Merck’s Healthcare business develops prescription medicines and related services focused on areas such as oncology, immunology, neurology (including therapies for multiple sclerosis) and fertility.
Recommended Stories
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.
